Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 9/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7098788 | 0.81 | HRH4 (0.43) | QPCT | |
| SCHEMBL7900339 | 0.80 | NAAA (0.48) | QPCT | |
| SCHEMBL7898979 | 0.80 | NAAA (0.48) | QPCT | |
| SCHEMBL7677658 | 0.80 | HRH4 (0.43) | QPCT | |
| SCHEMBL7902073 | 0.80 | NAAA (0.48) | QPCT | |
| SCHEMBL17554838 | 0.79 | QPCT (0.38) | QPCT | |
| SCHEMBL1309551 | 0.79 | QPCT (0.38) | QPCT | |
| SCHEMBL810972 | 0.78 | QPCT (0.51) | QPCTSMN1; SMN2NPC1 | |
| SCHEMBL7262289 | 0.77 | CYP1A2 (0.53) | QPCT | |
| SCHEMBL7261276 | 0.77 | CYP1A2 (0.53) | QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807682-B2 | Pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2010-10-05 | — | — | US | claimed |
| EP-1397355-B1 | PYRIDYL CYANOGUANIDINE COMPOUNDS | LEO PHARMA AS (DK) | 2009-09-09 | — | — | EP | claimed |
| US-20080090842-A1 | Novel pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2008-04-17 | — | — | US | claimed |
| US-7304066-B2 | Pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2007-12-04 | — | — | US | claimed |
| US-20040220408-A1 | Novel pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2004-11-04 | — | — | US | claimed |
| US-20120029036-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TIANJIN MICHELE SCI-TECH DEVELOPMENT CO., LTD. (CN) | 2012-02-02 | — | — | US | disclosed |
| EP-2394649-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDYL CYANOGUANIDINES, PREPARATION METHODS AND USES THEREOF | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2011-12-14 | — | — | EP | disclosed |
| US-7807682-B2 | Pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2010-10-05 | — | — | US | disclosed |
| EP-1397355-B1 | PYRIDYL CYANOGUANIDINE COMPOUNDS | LEO PHARMA AS (DK) | 2009-09-09 | — | — | EP | disclosed |
| US-20080090842-A1 | Novel pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2008-04-17 | — | — | US | disclosed |
| US-7304066-B2 | Pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2007-12-04 | — | — | US | disclosed |
| US-20040220408-A1 | Novel pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220408-A1 | Novel pyridyl cyanoguanidine compounds | DAO, AOC1, SIGMAR1 | QPCT 1391/4885SMN1; SMN2 2210/4885NPC1 1991/4885 |
| US-20080090842-A1 | Novel pyridyl cyanoguanidine compounds | DAO, CCNY, CBR1 | QPCT 1160/4885SMN1; SMN2 2438/4885NPC1 2229/4885 |
| US-20120029036-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF | PLPBP, PYGL, QDPR | QPCT 666/4885SMN1; SMN2 2943/4885NPC1 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.